[1] In 1995, Jonathan Ross Goodman and Mark Beaudet founded Paladin Labs, the predecessor company to Knight Therapeutics.

[2] In 2011, Goodman was seriously injured in a cycling accident, forcing him to temporarily relinquish the CEO role to Mark Beaudet.

[3] Also in 2011, Paladin offered to buy Afexa Life Sciences for $57 million, but was outbid by Valeant Pharmaceuticals.

[5] As part of the transaction, Knight Therapeutics was spun-off to the shareholders of Paladin, with the rights to Impavido, a leishmaniasis drug.

As of June 2020, the company commercializes dozens of innovative pharmaceuticals in Canada and 10 Latin American countries with a 700+ employees.